Deutsche Bank set a €115.00 ($133.72) price target on Bayer (FRA:BAYN) in a research report released on Friday. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the subject of a number of other reports. Goldman Sachs Group set a €116.00 ($134.88) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, September 5th. Barclays set a €105.00 ($122.09) price objective on Bayer and gave the stock a buy rating in a research report on Thursday, September 6th. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Bayer in a research report on Monday, October 22nd. Independent Research set a €69.00 ($80.23) price objective on Bayer and gave the stock a neutral rating in a research report on Friday, November 30th. Finally, Commerzbank set a €99.00 ($115.12) price objective on Bayer and gave the stock a buy rating in a research report on Tuesday, November 27th. Six research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Bayer has a consensus rating of Buy and an average price target of €90.80 ($105.58).

Bayer stock traded up €1.06 ($1.23) during mid-day trading on Friday, reaching €63.43 ($73.76). 5,377,233 shares of the company were exchanged. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.